Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terence Friedlander

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 11, 2024
Initial Experience with <sup>68</sup>Ga-FAP-2286 PET Imaging in Patients with Urothelial CancerVadim S Koshkin, Vipul Kumar, Brad Kline, et al.
JMIR Cancer|June 1, 2023
Engaging Men of Diverse Racial and Ethnic Groups With Advanced Prostate Cancer in the Design of an mHealth Diet and Exercise Intervention: Focus Group StudyElizabeth Y Wang, Hala T Borno, Samuel L Washington Iii, et al.
Urologic Oncology|February 6, 2017
A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium studyRahul Aggarwal, Alan Bryce, Charles J Ryan, et al.
The Journal of Urology|April 28, 2015
Circulating Tumor Cells as Potential Biomarkers in Bladder CancerAjjai Alva, Terence Friedlander, Melanie Clark, et al.
BMC Cancer|September 24, 2016
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patientsArchana Anantharaman, Terence Friedlander, David Lu, et al.
American Journal of Clinical Pathology|January 5, 2021
Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent PlasmaJoanna Balcerek, Evelin Trejo, Kendall Levine, et al.
Cancer|October 4, 2019
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108Peter H O'Donnell, Hendrick Tobias Arkenau, Srikala S Sridhar, et al.
Cancer Medicine|November 21, 2024
Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate CancerDaniel H Kwon, Lauren Trihy, Nika Darvish, et al.
The Lancet. Oncology|November 3, 2023
Single-dose <sup>177</sup>Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trialRahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, et al.
Urologic Oncology|July 26, 2021
A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II studyYaoYao Pollock, Li Zhang, Stacey A Kenfield, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 11, 2024
Initial Experience with <sup>68</sup>Ga-FAP-2286 PET Imaging in Patients with Urothelial CancerVadim S Koshkin, Vipul Kumar, Brad Kline, et al.
JMIR Cancer|June 1, 2023
Engaging Men of Diverse Racial and Ethnic Groups With Advanced Prostate Cancer in the Design of an mHealth Diet and Exercise Intervention: Focus Group StudyElizabeth Y Wang, Hala T Borno, Samuel L Washington Iii, et al.
Urologic Oncology|February 6, 2017
A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium studyRahul Aggarwal, Alan Bryce, Charles J Ryan, et al.
The Journal of Urology|April 28, 2015
Circulating Tumor Cells as Potential Biomarkers in Bladder CancerAjjai Alva, Terence Friedlander, Melanie Clark, et al.
BMC Cancer|September 24, 2016
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patientsArchana Anantharaman, Terence Friedlander, David Lu, et al.
American Journal of Clinical Pathology|January 5, 2021
Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent PlasmaJoanna Balcerek, Evelin Trejo, Kendall Levine, et al.
Cancer|October 4, 2019
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108Peter H O'Donnell, Hendrick Tobias Arkenau, Srikala S Sridhar, et al.
Cancer Medicine|November 21, 2024
Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate CancerDaniel H Kwon, Lauren Trihy, Nika Darvish, et al.
The Lancet. Oncology|November 3, 2023
Single-dose <sup>177</sup>Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trialRahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, et al.
Urologic Oncology|July 26, 2021
A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II studyYaoYao Pollock, Li Zhang, Stacey A Kenfield, et al.
Pageof 4